1. Home
  2. NRIX vs JBLU Comparison

NRIX vs JBLU Comparison

Compare NRIX & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

N/A

Current Price

$5.83

Market Cap

1.5B

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
JBLU
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Air Freight/Delivery Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
NRIX
JBLU
Price
$15.88
$5.83
Analyst Decision
Strong Buy
Sell
Analyst Count
13
12
Target Price
$29.46
$4.93
AVG Volume (30 Days)
844.9K
19.0M
Earning Date
05-01-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.83
EPS
N/A
N/A
Revenue
$76,987,000.00
$9,062,000,000.00
Revenue This Year
N/A
$10.10
Revenue Next Year
$29.30
$7.91
P/E Ratio
N/A
N/A
Revenue Growth
99.31
N/A
52 Week Low
$8.18
$3.34
52 Week High
$22.50
$6.92

Technical Indicators

Market Signals
Indicator
NRIX
JBLU
Relative Strength Index (RSI) 42.26 53.40
Support Level $15.62 $4.74
Resistance Level $19.98 $6.45
Average True Range (ATR) 0.78 0.36
MACD -0.03 -0.03
Stochastic Oscillator 36.46 35.85

Price Performance

Historical Comparison
NRIX
JBLU

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

Share on Social Networks: